KR20040064275A - 유전자 발현 프로파일을 이용한 질병의 동정, 모니터링,치료 및 생물학적 상태의 확인 - Google Patents

유전자 발현 프로파일을 이용한 질병의 동정, 모니터링,치료 및 생물학적 상태의 확인 Download PDF

Info

Publication number
KR20040064275A
KR20040064275A KR10-2004-7007103A KR20047007103A KR20040064275A KR 20040064275 A KR20040064275 A KR 20040064275A KR 20047007103 A KR20047007103 A KR 20047007103A KR 20040064275 A KR20040064275 A KR 20040064275A
Authority
KR
South Korea
Prior art keywords
data set
panel
gene expression
profile data
components
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR10-2004-7007103A
Other languages
English (en)
Korean (ko)
Inventor
마이클 베비락쿠아
존 씨. 체로니스
빅터 트리욘
다뉴트 엠. 반카이티스-데이비스
Original Assignee
소스 프리시전 메디슨, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27502635&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR20040064275(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 소스 프리시전 메디슨, 인코포레이티드 filed Critical 소스 프리시전 메디슨, 인코포레이티드
Publication of KR20040064275A publication Critical patent/KR20040064275A/ko
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16Z—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS, NOT OTHERWISE PROVIDED FOR
    • G16Z99/00—Subject matter not provided for in other main groups of this subclass
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57515—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the breast
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G16B25/10—Gene or protein expression profiling; Expression-ratio estimation or normalisation
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Genetics & Genomics (AREA)
  • Evolutionary Biology (AREA)
  • Medical Informatics (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Theoretical Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
KR10-2004-7007103A 2001-11-09 2002-11-08 유전자 발현 프로파일을 이용한 질병의 동정, 모니터링,치료 및 생물학적 상태의 확인 Ceased KR20040064275A (ko)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US34821301P 2001-11-09 2001-11-09
US60/348,213 2001-11-09
US34088101P 2001-12-07 2001-12-07
US60/340,881 2001-12-07
US36963302P 2002-04-03 2002-04-03
US60/369,633 2002-04-03
US37699702P 2002-04-30 2002-04-30
US60/376,997 2002-04-30
PCT/US2002/036084 WO2003040404A1 (en) 2001-11-09 2002-11-08 Identification, monitoring and treatment of disease and characterization of biological condition using gene expression profiles

Publications (1)

Publication Number Publication Date
KR20040064275A true KR20040064275A (ko) 2004-07-16

Family

ID=27502635

Family Applications (1)

Application Number Title Priority Date Filing Date
KR10-2004-7007103A Ceased KR20040064275A (ko) 2001-11-09 2002-11-08 유전자 발현 프로파일을 이용한 질병의 동정, 모니터링,치료 및 생물학적 상태의 확인

Country Status (7)

Country Link
US (4) US6964850B2 (https=)
EP (1) EP1451340B1 (https=)
JP (2) JP5236856B2 (https=)
KR (1) KR20040064275A (https=)
CN (2) CN1612936A (https=)
CA (1) CA2466502A1 (https=)
WO (1) WO2003040404A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017086675A1 (ko) * 2015-11-19 2017-05-26 연세대학교 산학협력단 대사 이상 질환 진단 장치 및 그 방법
KR20200038660A (ko) * 2018-10-04 2020-04-14 사회복지법인 삼성생명공익재단 바이오마커의 선별 방법 및 이를 이용한 암의 진단을 위한 정보제공방법

Families Citing this family (134)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7473528B2 (en) 1999-01-06 2009-01-06 Genenews Inc. Method for the detection of Chagas disease related gene transcripts in blood
US6960439B2 (en) 1999-06-28 2005-11-01 Source Precision Medicine, Inc. Identification, monitoring and treatment of disease and characterization of biological condition using gene expression profiles
US6905827B2 (en) 2001-06-08 2005-06-14 Expression Diagnostics, Inc. Methods and compositions for diagnosing or monitoring auto immune and chronic inflammatory diseases
US7235358B2 (en) * 2001-06-08 2007-06-26 Expression Diagnostics, Inc. Methods and compositions for diagnosing and monitoring transplant rejection
US7026121B1 (en) 2001-06-08 2006-04-11 Expression Diagnostics, Inc. Methods and compositions for diagnosing and monitoring transplant rejection
CN1612936A (zh) 2001-11-09 2005-05-04 苏尔斯精细医药公司 利用基因表达分布图识别、监控和治疗疾病以及鉴定生物学状态
CN100406567C (zh) * 2002-01-22 2008-07-30 生物材料公司 生物可降解聚合物的干燥方法
WO2004046098A2 (en) * 2002-05-16 2004-06-03 Vanderbilt University Method for predicting autoimmune diseases
US20040096917A1 (en) * 2002-11-12 2004-05-20 Becton, Dickinson And Company Diagnosis of sepsis or SIRS using biomarker profiles
WO2004044556A2 (en) 2002-11-12 2004-05-27 Becton, Dickinson And Company Diagnosis of sepsis or sirs using biomarker profiles
WO2004044555A2 (en) 2002-11-12 2004-05-27 Becton, Dickinson And Company Diagnosis of sepsis or sirs using biomarker profiles
AU2003295598B2 (en) 2002-11-15 2009-12-24 Genomic Health, Inc. Gene expression profiling of EGFR positive cancer
WO2004057034A1 (en) * 2002-12-19 2004-07-08 Source Precision Medicine, Inc. Identification, monitoring and treatment of infectious disease and characterization of inflammatory conditions related to infectious disease using gene expression profiles
US20040231909A1 (en) 2003-01-15 2004-11-25 Tai-Yang Luh Motorized vehicle having forward and backward differential structure
CA2515096A1 (en) * 2003-02-06 2004-08-26 Genomic Health, Inc. Gene expression markers for response to egfr inhibitor drugs
US20080014579A1 (en) * 2003-02-11 2008-01-17 Affymetrix, Inc. Gene expression profiling in colon cancers
CA2516553C (en) * 2003-02-20 2013-04-16 Genomic Health, Inc. Use of intronic rna to measure gene expression
US7892745B2 (en) 2003-04-24 2011-02-22 Xdx, Inc. Methods and compositions for diagnosing and monitoring transplant rejection
EP1636380A2 (en) * 2003-05-30 2006-03-22 Genomic Health, Inc. Gene expression markers for response to egfr inhibitor drugs
ES2609234T3 (es) 2003-06-24 2017-04-19 Genomic Health, Inc. Predicción de la probabilidad de recidiva de cáncer
DE602004024539D1 (de) * 2003-07-03 2010-01-21 Gentron Llc Verfahren und systeme zur diagnose von nicht das zentrale nervensystem (zns) betreffenden krankheiten in zns-proben
US7526387B2 (en) 2003-07-10 2009-04-28 Genomic Health, Inc. Expression profile algorithm and test for cancer prognosis
EP1668111A4 (en) 2003-08-08 2008-07-02 Genenews Inc OSTEOARTHRITIS BIOMARKERS AND USES THEREOF
CA2542656A1 (en) * 2003-10-16 2005-05-06 Genomic Health, Inc. Qrt-pcr assay system for gene expression profiling
CA2551267C (en) * 2003-12-23 2012-05-01 Genomic Health, Inc. Universal amplification of fragmented rna
CA2563074C (en) 2004-04-09 2014-05-20 Genomic Health, Inc. Gene expression markers for predicting response to chemotherapy
WO2006029184A2 (en) * 2004-09-08 2006-03-16 Expression Diagnostics, Inc. Genes useful for diagnosing and monitoring inflammation related disorders
EP1815014B1 (en) * 2004-11-05 2012-03-21 Genomic Health, Inc. Molecular indicators of breast cancer prognosis and prediction of treatment response
JP5020088B2 (ja) * 2004-11-05 2012-09-05 ジェノミック ヘルス， インコーポレイテッド 遺伝子発現マーカーを使用する、化学療法に対する反応の予測
US20060157647A1 (en) * 2005-01-18 2006-07-20 Becton, Dickinson And Company Multidimensional liquid chromatography/spectrometry
CA2605143A1 (en) 2005-04-15 2006-10-26 Becton, Dickinson And Company Diagnosis of sepsis
JP4800384B2 (ja) 2005-06-08 2011-10-26 ヒタチ ケミカル リサーチ センター インコーポレイテッド 腫瘍細胞及び刺激された白血球におけるｍＲＮＡの発現プロファイルに基づく腫瘍性疾患に対する免疫応答を予測する方法
JP5024583B2 (ja) * 2005-09-14 2012-09-12 ソニー株式会社 情報処理装置および情報処理方法、情報処理システム、プログラム、並びに、記録媒体
NZ593226A (en) 2006-01-11 2012-10-26 Genomic Health Inc Gene expression markers (efnb2) for colorectal cancer prognosis
WO2007123772A2 (en) 2006-03-31 2007-11-01 Genomic Health, Inc. Genes involved in estrogen metabolism
ATE518011T1 (de) * 2006-04-07 2011-08-15 Hitachi Chemical Co Ltd Erhöhte expression von t- zellenrezeptorvermittelter tumornekrosefaktorsuperfamilie und chemokin-mrna in peripheren blut leukozyten bei patienten mit morbus& xa;crohn
CN101438304A (zh) * 2006-05-10 2009-05-20 皇家飞利浦电子股份有限公司 为分类学习变换测量数据
AU2007254206A1 (en) * 2006-05-16 2007-11-29 Source Mdx Assessment of effect of an agent on a human biological condition using rodent gene expression panels
JP5470848B2 (ja) * 2006-08-04 2014-04-16 味の素株式会社 肺癌の評価方法、肺癌評価装置、肺癌評価方法、肺癌評価システム、肺癌評価プログラム、記録媒体、および、情報通信端末装置
WO2008021431A2 (en) 2006-08-14 2008-02-21 Xdx, Inc. Methods and compositions for diagnosing and monitoring the status of transplant rejection and immune disorders
US8148067B2 (en) 2006-11-09 2012-04-03 Xdx, Inc. Methods for diagnosing and monitoring the status of systemic lupus erythematosus
US20090104605A1 (en) * 2006-12-14 2009-04-23 Gary Siuzdak Diagnosis of sepsis
WO2008075664A1 (ja) * 2006-12-21 2008-06-26 Ajinomoto Co., Inc. 癌の評価方法、ならびに癌評価装置、癌評価方法、癌評価システム、癌評価プログラムおよび記録媒体
EP2096439A4 (en) 2006-12-21 2011-01-05 Ajinomoto Kk METHOD FOR ASSESSING COLORECTAL CARCINOMA, COLORECTAL CARCINOMA ASSESSMENT DEVICE, METHOD, SYSTEM, PROGRAM AND RECORDING MEDIUM
JP5746810B2 (ja) 2006-12-21 2015-07-08 味の素株式会社 乳癌の評価方法、ならびに乳癌評価装置、乳癌評価方法、乳癌評価システム、乳癌評価プログラムおよび記録媒体
US20090117562A1 (en) 2007-04-09 2009-05-07 Valerie Wailin Hu Method and kit for diagnosing Autism using gene expression profiling
US9551033B2 (en) 2007-06-08 2017-01-24 Genentech, Inc. Gene expression markers of tumor resistance to HER2 inhibitor treatment
EP2171090B1 (en) 2007-06-08 2013-04-03 Genentech, Inc. Gene expression markers of tumor resistance to her2 inhibitor treatment
WO2008154532A1 (en) * 2007-06-11 2008-12-18 California Pacific Medical Center Method and kit for dynamic gene expression monitoring
US8068994B2 (en) * 2007-07-27 2011-11-29 Wayne State University Method for analyzing biological networks
EP2209919A4 (en) 2007-11-14 2011-04-13 Hitachi Chemical Co Ltd ENHANCED EXPRESSION OF FC RECEPTOR TUMOR NECROSIS NECROSIS FACTOR SUPERFAMILY IN THE PERIFERIC BLOOD LEUKOCYTES
US10365279B2 (en) 2008-01-25 2019-07-30 Berg Llc Assay system for the assessment of oncogenicity, tumor progression, and treatment efficacy
CN101939652B (zh) * 2008-02-06 2015-01-07 味之素株式会社 胃癌的评价方法、以及胃癌评价装置、胃癌评价方法、胃癌评价系统、胃癌评价程序和记录介质
US8669113B2 (en) 2008-04-03 2014-03-11 Becton, Dickinson And Company Advanced detection of sepsis
US7776522B2 (en) * 2008-04-24 2010-08-17 Becton, Dickinson And Company Methods for diagnosing oncogenic human papillomavirus (HPV)
BRPI0913578A2 (pt) 2008-05-14 2017-06-06 Dermtech Int diagnose de melanoma e lentigo solar por análise de ácido nucléico
BRPI0812682A2 (pt) 2008-06-16 2010-06-22 Genentech Inc tratamento de cáncer de mama metastático
KR101821551B1 (ko) 2008-06-20 2018-01-25 아지노모토 가부시키가이샤 전립선 질환의 평가 방법
KR101817058B1 (ko) * 2008-06-20 2018-01-11 아지노모토 가부시키가이샤 여성 생식기암의 평가 방법
EP2977469A1 (en) * 2008-08-28 2016-01-27 Dermtech International Determining age ranges of skin samples
US8748103B2 (en) 2008-11-07 2014-06-10 Sequenta, Inc. Monitoring health and disease status using clonotype profiles
US9528160B2 (en) 2008-11-07 2016-12-27 Adaptive Biotechnolgies Corp. Rare clonotypes and uses thereof
US9365901B2 (en) 2008-11-07 2016-06-14 Adaptive Biotechnologies Corp. Monitoring immunoglobulin heavy chain evolution in B-cell acute lymphoblastic leukemia
US8628927B2 (en) 2008-11-07 2014-01-14 Sequenta, Inc. Monitoring health and disease status using clonotype profiles
US9506119B2 (en) 2008-11-07 2016-11-29 Adaptive Biotechnologies Corp. Method of sequence determination using sequence tags
US8691510B2 (en) * 2008-11-07 2014-04-08 Sequenta, Inc. Sequence analysis of complex amplicons
CN104195227B (zh) 2008-11-07 2017-04-12 适应生物技术公司 通过序列分析监测状况的方法
WO2011109440A1 (en) 2010-03-01 2011-09-09 Caris Life Sciences Luxembourg Holdings Biomarkers for theranostics
US20110229471A1 (en) 2008-11-26 2011-09-22 Cedars-Sinai Medical Center Methods of determining responsiveness to anti-tnf alpha therapy in inflammatory bowel disease
US9580752B2 (en) 2008-12-24 2017-02-28 Cedars-Sinai Medical Center Methods of predicting medically refractive ulcerative colitis (MR-UC) requiring colectomy
EP2387627B1 (en) 2009-01-15 2016-03-30 Adaptive Biotechnologies Corporation Adaptive immunity profiling and methods for generation of monoclonal antibodies
SG10201401722XA (en) * 2009-05-01 2014-08-28 Genomic Health Inc Gene expression profile algorithm and test for likelihood of recurrence of colorectal cancer andresponse to chemotherapy
CN102459643B (zh) 2009-06-25 2016-06-01 弗雷德哈钦森癌症研究中心 检测获得性免疫的方法
US9043160B1 (en) 2009-11-09 2015-05-26 Sequenta, Inc. Method of determining clonotypes and clonotype profiles
WO2011127219A1 (en) 2010-04-06 2011-10-13 Caris Life Sciences Luxembourg Holdings Circulating biomarkers for disease
JP5755326B2 (ja) 2010-06-11 2015-07-29 日立化成株式会社 腎機能の特徴を決定する方法
WO2011156734A2 (en) * 2010-06-11 2011-12-15 Hitachi Chemical Co., Ltd. Method of characterizing vascular diseases
MX338883B (es) 2010-07-27 2016-05-04 Genomic Health Inc Metodo para usar expresion de gen para determinar el pronostico de cancer de prostata.
US20130130933A1 (en) * 2010-08-12 2013-05-23 William Marsh Rice University Biomarker signatures for wellness testing
CA2818890C (en) 2010-11-23 2022-07-12 Krisani Biosciences (P) Ltd Method and system for prognosis and treatment of diseases using portfolio of genes
WO2012109435A1 (en) * 2011-02-12 2012-08-16 Siemens Healthcare Diagnostics Inc Environment and method for analysis of genetic sequence data
US9719129B2 (en) 2011-06-10 2017-08-01 Hitachi Chemical Co., Ltd. Methods for isolating vesicles from biological fluids
US10385475B2 (en) 2011-09-12 2019-08-20 Adaptive Biotechnologies Corp. Random array sequencing of low-complexity libraries
EP2768982A4 (en) 2011-10-21 2015-06-03 Adaptive Biotechnologies Corp QUANTIFICATION OF ADAPTIVE IMMUNOCELL GENOMES IN A COMPLEX MIX OF CELLS
EP3650117B1 (en) 2011-11-14 2022-07-20 Aushon Biosystems, Inc. Systems and methods to enhance consistency of assay performance
US9824179B2 (en) 2011-12-09 2017-11-21 Adaptive Biotechnologies Corp. Diagnosis of lymphoid malignancies and minimal residual disease detection
US9499865B2 (en) 2011-12-13 2016-11-22 Adaptive Biotechnologies Corp. Detection and measurement of tissue-infiltrating lymphocytes
US8725426B2 (en) 2012-01-31 2014-05-13 Genomic Health, Inc. Gene expression profile algorithm and test for determining prognosis of prostate cancer
DK2823060T3 (en) 2012-03-05 2018-05-28 Adaptive Biotechnologies Corp Determination of associated immune receptor chains from frequency-matched subunits
CA2872468C (en) 2012-05-08 2020-10-27 Adaptive Biotechnologies Corporation Compositions and methods for measuring and calibrating amplification bias in multiplexed pcr reactions
EA201492178A1 (ru) 2012-05-22 2015-12-30 Берг Ллк Основанные на клетках перекрестные анализы для идентификации маркеров индуцированной лекарственными средствами токсичности
FR2993282B1 (fr) * 2012-07-13 2017-11-10 Expanscience Lab Procede d'identification de marqueurs moleculaires de la peau d'enfant
NZ706155A (en) * 2012-09-12 2018-09-28 Berg Llc Use of markers in the identification of cardiotoxic agents
US10984888B2 (en) * 2012-09-14 2021-04-20 Life Technologies Corporation Methods and systems for a digital PCR experiment designer
JP6449160B2 (ja) 2012-10-01 2019-01-09 アダプティブ バイオテクノロジーズ コーポレイション 適応免疫受容体多様性およびクローン性特性決定による免疫能力評価関連出願の相互参照
US10150996B2 (en) 2012-10-19 2018-12-11 Adaptive Biotechnologies Corp. Quantification of adaptive immune cell genomes in a complex mixture of cells
KR102343212B1 (ko) 2013-03-27 2021-12-23 세다르스-신나이 메디칼 센터 Tl1a 기능 및 관련된 신호전달 경로의 저해에 의한 섬유증 및 염증의 완화 및 반전
JP6297676B2 (ja) 2013-05-06 2018-03-20 日立化成株式会社 標的分子を捕捉するためのデバイス及び方法
US9708657B2 (en) 2013-07-01 2017-07-18 Adaptive Biotechnologies Corp. Method for generating clonotype profiles using sequence tags
WO2015010108A1 (en) 2013-07-19 2015-01-22 Cedars-Sinai Medical Center Signature of tl1a (tnfsf15) signaling pathway
PL3084664T3 (pl) * 2013-12-16 2020-10-05 Philip Morris Products S.A. Układy i sposoby do przewidywania statusu palenia u osobnika
US10364469B2 (en) * 2014-01-16 2019-07-30 Illumina, Inc Gene expression panel for prognosis of prostate cancer recurrence
WO2019161126A1 (en) 2018-02-14 2019-08-22 Dermtech, Inc. Novel gene classifiers and uses thereof in non-melanoma skin cancers
WO2015134787A2 (en) 2014-03-05 2015-09-11 Adaptive Biotechnologies Corporation Methods using randomer-containing synthetic molecules
US10066265B2 (en) 2014-04-01 2018-09-04 Adaptive Biotechnologies Corp. Determining antigen-specific t-cells
WO2016011434A1 (en) * 2014-07-18 2016-01-21 Landis Darryl Use of an evidence-based, translational algorithm to, inter alia, assess biomarkers
CA2966201A1 (en) 2014-10-29 2016-05-06 Adaptive Biotechnologies Corp. Highly-multiplexed simultaneous detection of nucleic acids encoding paired adaptive immune receptor heterodimers from many samples
US10266895B2 (en) 2014-11-05 2019-04-23 Hitachi Chemical Company Ltd. Exosomes and microvesicles in intestinal luminal fluids and stool and use of same for the assessment of inflammatory bowel disease
US10370719B2 (en) 2014-11-12 2019-08-06 Hitachi Chemical Co., Ltd. Method and device for diagnosing organ injury
US10246701B2 (en) 2014-11-14 2019-04-02 Adaptive Biotechnologies Corp. Multiplexed digital quantitation of rearranged lymphoid receptors in a complex mixture
WO2016086029A1 (en) 2014-11-25 2016-06-02 Adaptive Biotechnologies Corporation Characterization of adaptive immune response to vaccination or infection using immune repertoire sequencing
CA2976580A1 (en) 2015-02-24 2016-09-01 Adaptive Biotechnologies Corp. Methods for diagnosing infectious disease and determining hla status using immune repertoire sequencing
AU2016242967B2 (en) 2015-04-01 2021-07-01 Adaptive Biotechnologies Corp. Method of identifying human compatible T cell receptors specific for an antigenic target
JP6232689B2 (ja) 2015-06-25 2017-11-22 株式会社国際電気通信基礎技術研究所 多器官連関システムを基盤とした予測装置、及び予測プログラム
BR112018000560A2 (pt) * 2015-07-13 2018-09-11 Koninklijke Philips Nv método para rastrear a disseminação da infecção, e sistema para rastrear a disseminação da infecção
DE112016003948T5 (de) 2015-08-31 2018-05-09 City Of Sapporo Molekulare verfahren zum beurteilen einer urothelialen erkrankung
CN105279397B (zh) * 2015-10-26 2017-12-19 华东交通大学 一种识别蛋白质相互作用网络中关键蛋白质的方法
US11186872B2 (en) 2016-03-17 2021-11-30 Cedars-Sinai Medical Center Methods of diagnosing inflammatory bowel disease through RNASET2
EP3466446B1 (en) 2016-03-29 2023-12-27 Karydo Therapeutix, Inc. Pharmaceutical composition or food composition, and method for assessing effect of active ingredient in vivo
CN114594268A (zh) 2016-03-29 2022-06-07 无限生物制药公司 用以预防或治疗肾脏疾病的活性组分的候选物质的筛选装置和筛选方法
US10607720B2 (en) 2016-05-11 2020-03-31 International Business Machines Corporation Associating gene expression data with a disease name
US10428325B1 (en) 2016-09-21 2019-10-01 Adaptive Biotechnologies Corporation Identification of antigen-specific B cell receptors
CN106709267A (zh) * 2017-01-25 2017-05-24 武汉贝纳科技服务有限公司 数据获取方法及装置
CN107058521B (zh) * 2017-03-17 2019-12-27 中国科学院北京基因组研究所 一种检测人体免疫状态的检测系统
JPWO2019066044A1 (ja) 2017-09-29 2020-12-10 ファーマバイオ株式会社 標準化発現量を利用した再生医療製品等の品質管理の手法
US11254980B1 (en) 2017-11-29 2022-02-22 Adaptive Biotechnologies Corporation Methods of profiling targeted polynucleotides while mitigating sequencing depth requirements
CN112136048A (zh) * 2018-02-21 2020-12-25 艾迪菲斯健康有限公司 测量全身性慢性炎性衰老的方法
EP3765853B1 (en) * 2018-03-13 2024-05-01 Creatv Microtech, Inc. Methods for monitoring treatment response and disease progression in subjects using circulating cells
WO2019193241A1 (en) * 2018-04-03 2019-10-10 Nokia Technologies Oy Use of band combination index for definition of carrier aggregation configurations
WO2020198229A1 (en) 2019-03-26 2020-10-01 Dermtech, Inc. Novel gene classifiers and uses thereof in skin cancers
CN113678074B (zh) * 2019-03-26 2025-05-09 杰富意钢铁株式会社 工艺状态监视装置以及工艺状态监视方法
WO2021119499A1 (en) * 2019-12-13 2021-06-17 Janssen Biotech, Inc. Materials and methods for inflammatory molecular markers
WO2023191555A1 (ko) * 2022-03-30 2023-10-05 국립암센터 만성 간질환 위험도 예측, 진단 또는 예후 예측용 마커로서 ifi16 돌연변이 유전자 및 이의 용도
CN118298911B (zh) * 2024-04-12 2024-11-22 中山大学孙逸仙纪念医院 一种多部位慢性疼痛潜在治疗靶点确定系统

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5800992A (en) * 1989-06-07 1998-09-01 Fodor; Stephen P.A. Method of detecting nucleic acids
US5580722A (en) * 1989-07-18 1996-12-03 Oncogene Science, Inc. Methods of determining chemicals that modulate transcriptionally expression of genes associated with cardiovascular disease
US5569601A (en) * 1990-12-07 1996-10-29 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education On Behalf Of The Oregon Health Sciences University Human dopamine receptor and its uses
US6114114A (en) 1992-07-17 2000-09-05 Incyte Pharmaceuticals, Inc. Comparative gene transcript analysis
DK0680517T4 (da) * 1993-01-21 2005-05-02 Harvard College Fremgangsmåde og diagnostiske sæt til bestemmelse af en forbindelses toksicitet under anvendelse afstress-promotorer fra pattedyr
US5643765A (en) * 1993-04-06 1997-07-01 University Of Rochester Method for quantitative measurement of gene expression using multiplex competitive reverse transcriptase-polymerase chain reaction
IL109382A (en) * 1993-04-21 2005-08-31 Univ Edinburgh In vitro method for inserting a heterologous gene
US6309823B1 (en) * 1993-10-26 2001-10-30 Affymetrix, Inc. Arrays of nucleic acid probes for analyzing biotransformation genes and methods of using the same
US7625697B2 (en) * 1994-06-17 2009-12-01 The Board Of Trustees Of The Leland Stanford Junior University Methods for constructing subarrays and subarrays made thereby
US5506145A (en) * 1994-12-02 1996-04-09 Bull; Brian S. Determination of an individual's inflammation index from whole blood fibrinogen and hematocrit or hemoglobin measurements
US5696127A (en) * 1994-12-22 1997-12-09 Ligand Pharmaceuticals Incorporated Steroid receptor modulator compounds and methods
US5968770A (en) * 1995-02-10 1999-10-19 Millennium Pharmaceuticals, Inc. Compositions and methods for the treatment and diagnosis of cardiovascular disease using rchd523 as a target
US6022683A (en) * 1996-12-16 2000-02-08 Nova Molecular Inc. Methods for assessing the prognosis of a patient with a neurodegenerative disease
US5866330A (en) * 1995-09-12 1999-02-02 The Johns Hopkins University School Of Medicine Method for serial analysis of gene expression
US5922184A (en) 1997-07-21 1999-07-13 Bio-Rad Laboratories, Inc. Computer-directed detection of paraproteins
FR2775984B1 (fr) 1998-03-11 2006-09-15 Bioscreen Therapeutics Sa Criblage differentiel qualitatif
ATE335843T1 (de) 1996-05-02 2006-09-15 Applera Corp Quantifizierung von rna-transkripten mittels genomischer dna als internen standard der amplifizierungsreaktion
US5955269A (en) * 1996-06-20 1999-09-21 Rutgers, The State University Of New Jersey Methods of screening foods for nutraceuticals
US6146828A (en) * 1996-08-14 2000-11-14 Exact Laboratories, Inc. Methods for detecting differences in RNA expression levels and uses therefor
EP0960214A4 (en) 1996-12-06 2004-08-04 Urocor Inc Diagnosis of disease status on HAnd from mRNA profiles
JPH10261029A (ja) 1996-12-16 1998-09-29 Nissho Corp アルツハイマー病生涯罹病性の予測システム
US5968784A (en) * 1997-01-15 1999-10-19 Chugai Pharmaceutical Co., Ltd. Method for analyzing quantitative expression of genes
US6165709A (en) * 1997-02-28 2000-12-26 Fred Hutchinson Cancer Research Center Methods for drug target screening
US5994076A (en) * 1997-05-21 1999-11-30 Clontech Laboratories, Inc. Methods of assaying differential expression
WO1999011822A1 (en) 1997-09-03 1999-03-11 Gene Logic Inc. Method for predicting prognosis and treatment response for genetically based abnormalities
EP1027456B1 (en) 1997-10-31 2005-03-16 Affymetrix, Inc. (a Delaware Corporation) Expression profiles in adult and fetal organs
JP3784162B2 (ja) 1998-01-14 2006-06-07 株式会社日立製作所 Ｄｎａ断片分析法
CA2318984C (en) 1998-02-25 2009-04-28 The United States Of America As Represented By The Secretary Department Of Health And Human Services Tumor tissue microarrays for rapid molecular profiling
KR20010034814A (ko) 1998-04-23 2001-04-25 제넨테크, 인크. 유전자 발현의 정량적 분석
EP1075485A4 (en) 1998-05-05 2004-12-15 Gene Logic Inc METHOD FOR EXAMINING GENE EXPRESSION IN T LYMPHOCYTES
US6232065B1 (en) * 1998-05-06 2001-05-15 Case Western Reserve University Analysis of gene family expression
US6324479B1 (en) * 1998-05-08 2001-11-27 Rosetta Impharmatics, Inc. Methods of determining protein activity levels using gene expression profiles
JP2002514804A (ja) 1998-05-12 2002-05-21 ロゼッタ インファーマティクス， インコーポレーテッド 遺伝子発現分析のための数値化方法、システムおよび装置
US6218122B1 (en) * 1998-06-19 2001-04-17 Rosetta Inpharmatics, Inc. Methods of monitoring disease states and therapies using gene expression profiles
US6132969A (en) * 1998-06-19 2000-10-17 Rosetta Inpharmatics, Inc. Methods for testing biological network models
DE69912444T3 (de) 1998-08-25 2010-05-06 University Of Washington, Seattle Schnelle quantitative analyse von proteinen oder proteinfunktionen in komplexen gemischen
US6185561B1 (en) * 1998-09-17 2001-02-06 Affymetrix, Inc. Method and apparatus for providing and expression data mining database
US6245517B1 (en) * 1998-09-29 2001-06-12 The United States Of America As Represented By The Department Of Health And Human Services Ratio-based decisions and the quantitative analysis of cDNA micro-array images
EP1121471A1 (en) 1998-10-13 2001-08-08 Clontech Laboratories, Inc. Nucleic acid arrays
US6203987B1 (en) * 1998-10-27 2001-03-20 Rosetta Inpharmatics, Inc. Methods for using co-regulated genesets to enhance detection and classification of gene expression patterns
JP4338316B2 (ja) 1998-11-05 2009-10-07 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド 遺伝子発現概要の作製方法
US6222093B1 (en) * 1998-12-28 2001-04-24 Rosetta Inpharmatics, Inc. Methods for determining therapeutic index from gene expression profiles
AU3326000A (en) * 1999-03-26 2000-10-16 George Hosokawa Means of early examination of malignant tumor
AU4698600A (en) * 1999-05-05 2000-11-17 Ut-Battelle, Llc Method and apparatus for combinatorial chemistry
ATE443295T1 (de) 1999-05-25 2009-10-15 Aventis Pharma Inc Mathematische analyse für die beurteilung von änderungen auf genexpressionsebene
ES2290046T3 (es) 1999-06-28 2008-02-16 Source Precision Medicine, Inc. Procedimiento para caracterizar un estado biologico, mediante el empleo de perfiles calibrados de expresion genica.
WO2001011082A2 (en) 1999-08-09 2001-02-15 Affymetrix, Inc. Methods of gene expression monitoring
US6569624B1 (en) 1999-08-12 2003-05-27 Wisconsin Alumni Research Foundation Identification of genetic markers of biological age and metabolism
AU7709300A (en) 1999-09-24 2001-04-24 Linden Technologies, Inc. Drug discovery using gene expression profiling
US6505125B1 (en) 1999-09-28 2003-01-07 Affymetrix, Inc. Methods and computer software products for multiple probe gene expression analysis
AU1179001A (en) 1999-10-13 2001-04-23 Plant Research International B.V. Method for detecting differences in gene expression between wild type plants andnewly developed plants
US6607885B1 (en) 1999-10-15 2003-08-19 E. I. Du Pont De Nemours And Company Method for high-density microarray medicated gene expression profiling
AU784861B2 (en) 1999-10-21 2006-07-06 Case Western Reserve University Gene expression profiling of inflammatory bowel disease
MXPA02004241A (es) 1999-10-26 2002-10-17 Digital Gene Tech Inc Regulacion de la expresion de genes por agentes neurolepticos.
WO2001032928A2 (en) 1999-11-05 2001-05-10 Phase-1 Molecular Toxicology Methods of determining individual hypersensitivity to an agent
US6248535B1 (en) 1999-12-20 2001-06-19 University Of Southern California Method for isolation of RNA from formalin-fixed paraffin-embedded tissue specimens
US7157227B2 (en) * 2000-03-31 2007-01-02 University Of Louisville Research Foundation Microarrays to screen regulatory genes
US7384736B2 (en) * 2001-09-06 2008-06-10 Decode Genetics Ehf. Methods for predicting drug sensitivity in patients afflicted with an inflammatory disease
CN1612936A (zh) 2001-11-09 2005-05-04 苏尔斯精细医药公司 利用基因表达分布图识别、监控和治疗疾病以及鉴定生物学状态

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017086675A1 (ko) * 2015-11-19 2017-05-26 연세대학교 산학협력단 대사 이상 질환 진단 장치 및 그 방법
KR20200038660A (ko) * 2018-10-04 2020-04-14 사회복지법인 삼성생명공익재단 바이오마커의 선별 방법 및 이를 이용한 암의 진단을 위한 정보제공방법

Also Published As

Publication number Publication date
US8718946B2 (en) 2014-05-06
JP5236856B2 (ja) 2013-07-17
US20030219771A1 (en) 2003-11-27
EP1451340A1 (en) 2004-09-01
CN1612936A (zh) 2005-05-04
JP2011067214A (ja) 2011-04-07
JP2005508505A (ja) 2005-03-31
US20100086935A1 (en) 2010-04-08
CN102402650A (zh) 2012-04-04
US8055452B2 (en) 2011-11-08
EP1451340A4 (en) 2007-04-11
US20120077199A1 (en) 2012-03-29
EP1451340B1 (en) 2014-01-08
WO2003040404A1 (en) 2003-05-15
US20050287576A1 (en) 2005-12-29
CA2466502A1 (en) 2003-05-15
US6964850B2 (en) 2005-11-15

Similar Documents

Publication Publication Date Title
US6960439B2 (en) Identification, monitoring and treatment of disease and characterization of biological condition using gene expression profiles
US6964850B2 (en) Identification, monitoring and treatment of disease and characterization of biological condition using gene expression profiles
US20180060481A1 (en) Identification, monitoring and treatment of infectious disease and characterization of inflammatory conditions related to infectious disease using gene expression profiles
Grigoriadis et al. Establishment of the epithelial-specific transcriptome of normal and malignant human breast cells based on MPSS and array expression data
US7935482B2 (en) Gene expression profiling for identification monitoring and treatment of rheumatoid arthritis
Raeber et al. Interleukin-2 immunotherapy reveals human regulatory T cell subsets with distinct functional and tissue-homing characteristics
Reka et al. Epithelial–mesenchymal transition-associated secretory phenotype predicts survival in lung cancer patients
US20040219568A1 (en) Systems and methods for characterizing a biological conditions or agent using selected gene expression profiles
JP2005508505A5 (https=)
Ius et al. An NF-κB signature predicts low-grade glioma prognosis: A precision medicine approach based on patient-derived stem cells
Goldberg et al. Human in vivo dose-response to controlled, low-dose low linear energy transfer ionizing radiation exposure
AU2003303238B2 (en) Identification, monitoring and treatment of infectious disease and characterization of inflammatory conditions related to infectious disease using gene expression profiles
Tao et al. Differential gene expression profiles of whole lesions from patients with oral lichen planus
CN113252900A (zh) 基于ApoA的慢性淋巴细胞白血病预后风险评估系统及其应用
US20110092390A1 (en) Assessment of effect of an agent on a human biological condition using rodent gene expression panels
Ranti et al. Elevated HLA-E and NKG2A as a consequence of chronic immune activation defines resistance to M. bovis BCG immunotherapy in Non-Muscle-Invasive Bladder Cancer
Pan et al. Chemoresistance and Immune Suppression in Gastric Cancer Are Driven by PPDPF Overexpression
Quan et al. Bioinformatics Analysis of C3 and CXCR4 act as Potential Prognostic Biomarkers in Clear Cell Renal Cell Carcinoma (ccRCC)
Wu et al. Identification of STAT5A as drug screening biomarker and immune checkpoint inhibitor in stomach adenocarcinoma via comprehensive bioinformatics analysis
Sweeney A Systems Biology Approach to Link Nuclear Factor Kappa B Activation with Lethal Prostate Cancer

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

R15-X000 Change to inventor requested

St.27 status event code: A-3-3-R10-R15-oth-X000

R16-X000 Change to inventor recorded

St.27 status event code: A-3-3-R10-R16-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000